Markowska A, Sajdak S
Eur J Gynaecol Oncol. 2017;38(2):181-183.
Despite the introduction of "the golden standard" in chemotherapy for ovarian cancer (taxanes/platinum), a relapse of the disease is noted in 80% of women treated in this manner. Studies on ovarian cancer stem cells (CSCs) and attempts at treatment using salinomycin, isolated from Streptonzyces albus and endotoxin of Clostridium peifringens, are promising, in particular because CSC markers have been identified. Resistence of ovarian cancer cells to paclitaxel and cisplatin is associated with a reduced expression of miR-30c, miR-130, and miR335, which results in activation of M-CSF, the known factor of resistance to cytostatic drugs. In clear cell ovarian cancer, a reduced expression of miR-449 was detected, which may lead to overexpression of MET phenotype, typical for chemoresistant ovarian cancer. MicroRNAs remain in investigations, but their involvement in the control of genes linked to the development of the cancer and its progression seems to offer the promise of a targeted therapy.
尽管卵巢癌化疗引入了“金标准”（紫杉烷类/铂类），但以这种方式治疗的女性中仍有80%会出现疾病复发。对卵巢癌干细胞（CSCs）的研究以及使用从白色链霉菌中分离出的沙利霉素和产气荚膜梭菌内毒素进行治疗的尝试很有前景，特别是因为已经鉴定出了CSC标志物。卵巢癌细胞对紫杉醇和顺铂的耐药性与miR-30c、miR-130和miR335的表达降低有关，这会导致M-CSF激活，M-CSF是已知的对细胞毒性药物耐药的因素。在透明细胞卵巢癌中，检测到miR-449表达降低，这可能导致MET表型过度表达，这是化疗耐药性卵巢癌的典型特征。微小RNA仍在研究中，但它们参与控制与癌症发生和进展相关的基因，似乎为靶向治疗带来了希望。
